Gregory D Lewis1, Adriaan A Voors2, Alain Cohen-Solal3, Marco Metra4, David J Whellan5, Justin A Ezekowitz6, Michael Böhm7,8, John R Teerlink9, Kieran F Docherty10, Renato D Lopes11, Punag H Divanji12, Stephen B Heitner12, Stuart Kupfer12, Fady I Malik12, Lisa Meng12, Amy Wohltman12, G Michael Felker11. 1. Division of Cardiology, Massachusetts General Hospital, Boston. 2. Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands. 3. Paris University, UMR-S 942, Department of Cardiology, Lariboisiere Hospital, Assistance Publique Hopitaux de Paris, Paris, France. 4. Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. 5. Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. 6. Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 7. Department of Internal Medicine, Saarland University, Homburg, Saarland, Germany. 8. Department of Cardiology, Saarland University, Homburg, Saarland, Germany. 9. Section of Cardiology, San Francisco Veterans Affairs Medical Center and University of California, San Francisco. 10. BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland. 11. Division of Cardiology, School of Medicine, Duke University Medical Center, Durham, North Carolina. 12. Cytokinetics, Incorporated, South San Francisco, California.
Abstract
Importance: Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF) but is not consistently improved by any of the current guideline-directed medical therapies. Objective: To determine whether omecamtiv mecarbil, a novel direct myosin activator that improves cardiac performance and reduces the risk for cardiovascular death or first HF event in HFrEF, can improve peak exercise capacity in patients with chronic HFrEF. Design, Setting, and Participants: Phase 3, double-blind, placebo-controlled randomized trial of patients with HFrEF (left ventricular ejection fraction ≤35%), New York Heart Association class II-III symptoms, N-terminal pro-B-type natriuretic peptide level of 200 pg/mL or greater, and baseline peak oxygen uptake (V̇o2) of 75% or less of predicted. Patients were randomized in a 2:1 ratio (omecamtiv mecarbil to placebo) between March 2019 and May 2021 at 63 sites in North America and Europe, with the last patient visit occurring on November 29, 2021. Interventions: Omecamtiv mecarbil (n = 185) or matching placebo (n = 91), given orally twice daily at a dose of 25 mg, 37.5 mg, or 50 mg based on target plasma levels, for 20 weeks. Main Outcomes and Measures: The primary end point was a change in exercise capacity (peak V̇o2) from baseline to week 20. Secondary end points included total workload, ventilatory efficiency, and daily physical activity as determined by accelerometry. Results: Among 276 patients who were randomized (median age, 64 years; IQR, 55-70 years; 42 women [15%]), 249 (90%) completed the trial. The median left ventricular ejection fraction was 28% (IQR, 21-33) and the median baseline peak V̇o2 was 14.2 mL/kg/min (IQR, 11.6-17.4) in the omecamtiv mecarbil group and 15.0 mL/kg/min (IQR, 12.0-17.2) in the placebo group. Mean change in peak V̇o2 did not differ significantly between the omecamtiv mecarbil and placebo groups (mean, -0.24 mL/kg/min vs 0.21 mL/kg/min; least square mean difference, -0.45 mL/kg/min [95% CI, -1.02 to 0.13]; P = .13). Adverse events included dizziness (omecamtiv mecarbil: 4.9%, placebo: 5.5%), fatigue (omecamtiv mecarbil: 4.9%, placebo: 4.4%), heart failure events (omecamtiv mecarbil: 4.9%, placebo: 4.4%), death (omecamtiv mecarbil: 1.6%, placebo: 1.1%), stroke (omecamtiv mecarbil: 0.5%, placebo: 1.1%), and myocardial infarction (omecamtiv mecarbil: 0%, placebo: 1.1%). Conclusions and Relevance: In patients with chronic HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. These findings do not support the use of omecamtiv mecarbil for treatment of HFrEF for improvement of exercise capacity. Trial Registration: ClinicalTrials.gov Identifier: NCT03759392.
Importance: Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF) but is not consistently improved by any of the current guideline-directed medical therapies. Objective: To determine whether omecamtiv mecarbil, a novel direct myosin activator that improves cardiac performance and reduces the risk for cardiovascular death or first HF event in HFrEF, can improve peak exercise capacity in patients with chronic HFrEF. Design, Setting, and Participants: Phase 3, double-blind, placebo-controlled randomized trial of patients with HFrEF (left ventricular ejection fraction ≤35%), New York Heart Association class II-III symptoms, N-terminal pro-B-type natriuretic peptide level of 200 pg/mL or greater, and baseline peak oxygen uptake (V̇o2) of 75% or less of predicted. Patients were randomized in a 2:1 ratio (omecamtiv mecarbil to placebo) between March 2019 and May 2021 at 63 sites in North America and Europe, with the last patient visit occurring on November 29, 2021. Interventions: Omecamtiv mecarbil (n = 185) or matching placebo (n = 91), given orally twice daily at a dose of 25 mg, 37.5 mg, or 50 mg based on target plasma levels, for 20 weeks. Main Outcomes and Measures: The primary end point was a change in exercise capacity (peak V̇o2) from baseline to week 20. Secondary end points included total workload, ventilatory efficiency, and daily physical activity as determined by accelerometry. Results: Among 276 patients who were randomized (median age, 64 years; IQR, 55-70 years; 42 women [15%]), 249 (90%) completed the trial. The median left ventricular ejection fraction was 28% (IQR, 21-33) and the median baseline peak V̇o2 was 14.2 mL/kg/min (IQR, 11.6-17.4) in the omecamtiv mecarbil group and 15.0 mL/kg/min (IQR, 12.0-17.2) in the placebo group. Mean change in peak V̇o2 did not differ significantly between the omecamtiv mecarbil and placebo groups (mean, -0.24 mL/kg/min vs 0.21 mL/kg/min; least square mean difference, -0.45 mL/kg/min [95% CI, -1.02 to 0.13]; P = .13). Adverse events included dizziness (omecamtiv mecarbil: 4.9%, placebo: 5.5%), fatigue (omecamtiv mecarbil: 4.9%, placebo: 4.4%), heart failure events (omecamtiv mecarbil: 4.9%, placebo: 4.4%), death (omecamtiv mecarbil: 1.6%, placebo: 1.1%), stroke (omecamtiv mecarbil: 0.5%, placebo: 1.1%), and myocardial infarction (omecamtiv mecarbil: 0%, placebo: 1.1%). Conclusions and Relevance: In patients with chronic HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. These findings do not support the use of omecamtiv mecarbil for treatment of HFrEF for improvement of exercise capacity. Trial Registration: ClinicalTrials.gov Identifier: NCT03759392.
Authors: Fady I Malik; James J Hartman; Kathleen A Elias; Bradley P Morgan; Hector Rodriguez; Katjusa Brejc; Robert L Anderson; Sandra H Sueoka; Kenneth H Lee; Jeffrey T Finer; Roman Sakowicz; Ramesh Baliga; David R Cox; Marc Garard; Guillermo Godinez; Raja Kawas; Erica Kraynack; David Lenzi; Pu Ping Lu; Alexander Muci; Congrong Niu; Xiangping Qian; Daniel W Pierce; Maria Pokrovskii; Ion Suehiro; Sheila Sylvester; Todd Tochimoto; Corey Valdez; Wenyue Wang; Tatsuo Katori; David A Kass; You-Tang Shen; Stephen F Vatner; David J Morgans Journal: Science Date: 2011-03-18 Impact factor: 47.728
Authors: B M Massie; M Conway; B Rajagopalan; R Yonge; S Frostick; J Ledingham; P Sleight; G Radda Journal: Circulation Date: 1988-08 Impact factor: 29.690
Authors: Gregory D Lewis; Kieran F Docherty; Adriaan A Voors; Alain Cohen-Solal; Marco Metra; David J Whellan; Justin A Ezekowitz; Piotr Ponikowski; Michael Böhm; John R Teerlink; Stephen B Heitner; Stuart Kupfer; Fady I Malik; Lisa Meng; G Michael Felker Journal: Circ Heart Fail Date: 2022-03-03 Impact factor: 8.790
Authors: Ijsbrand T Klip; Josep Comin-Colet; Adriaan A Voors; Piotr Ponikowski; Cristina Enjuanes; Waldemar Banasiak; Dirk J Lok; Piotr Rosentryt; Ainhoa Torrens; Lech Polonski; Dirk J van Veldhuisen; Peter van der Meer; Ewa A Jankowska Journal: Am Heart J Date: 2013-02-22 Impact factor: 4.749
Authors: Yuan Lu; Paul W Jones; Karthik Murugiah; César Caraballo; Daisy S Massey; Shiwani Mahajan; Rezwan Ahmed; Eric M Bader; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2022-01-25 Impact factor: 24.094
Authors: Suzanne N Voorrips; Huitzilihuitl Saucedo-Orozco; Pablo I Sánchez-Aguilera; Rudolf A De Boer; Peter Van der Meer; B Daan Westenbrink Journal: Int J Mol Sci Date: 2022-08-03 Impact factor: 6.208